Obstacles to Immunization in Children with Juvenile Idiopathic Arthritis

Image
legacy health gastroenterology :: Article Creator Legacy Health Agrees To $14.5M Settlement Over Claims Nurses, Others ... Legacy Health and its hospitals have agreed to pay $14.5 million to settle a class action suit filed by about 17,000 current and former non-exempt employees who said the health system failed to compensate them for work during meal breaks or performed while technically "off-the-clock,'' the lawsuit alleges. Lawyers for both sides reached the settlement after holding two mediation sessions, according to court records. If you purchase a product or register for an account through a link on our site, we may receive compensation. By using this site, you consent to our User Agreement and agree that your clicks, interactions, and personal information may be collected, recorded, and/or stored by us and social media and other third-party partners in accordance with our Privacy Policy. Legacy Health May Soon Go Out O...

Priming the body's immune system with personalized cancer vaccines - Genetic Literacy Project

In 2014, at Washington University School of Medicine in St. Louis, six melanoma patients received infusions of an anticancer vaccine composed of their own dendritic cells. Our WashU colleagues had extracted immune cells from the patients’ blood two months earlier, cultured them in the lab, and mixed in peptides selected and synthesized based on specific mutations present in the genomes of each patient’s tumor…

This first test of personalized cancer vaccines in people grew out of our collaborative efforts to develop a computational pipeline to identify tumor-unique mutations that could induce immune responses in cancer patients, helping them to fight their diseases. … In contrast to cell-based immune therapies, which directly provide the patient with tumor-attacking T cells, the idea was that these neoantigens could be used to create vaccines that stimulate the differentiation of endogenous killer T cells.

These results indicated that it was possible to prime the immune system to recognize nonself, cancer-specific peptides and to elicit an antitumor T cell response that targets cancer cells.

Since the publication of our personalized melanoma vaccine trial, three subsequent studies have demonstrated the potential of neoantigen-based vaccines in treating human cancers. Both academic and industry sponsors are now conducting many more such clinical trials.

Read full, original post: Personalized Cancer Vaccines in Clinical Trials



https://ift.tt/2K8jReI

Comments

Popular posts from this blog

180+ chief medical officers to know | 2025

Primary Care - North Greece Internal Medicine & Pediatrics

Screening and Testing for Hepatitis B Virus Infection ...